Evidence map›Paper›PMID 40229218›Full record

ArticleTherapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy2025

Rheocarna treatment for non-dialysis patients.

Atsushi Ohkubo, Takatoshi Sakurasawa, Yuki Hoshikawa, Masaya Deushi, Mana Usui, Shigeto Komori, Ayako Itagaki, Hiroko Yamamoto, Hiroshi Seshima, Naoki Kurashima and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Rheocarna treatment for non-dialysis patients.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Atsushi OhkuboMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Takatoshi SakurasawaMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Yuki HoshikawaMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Masaya DeushiMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Mana UsuiMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Shigeto KomoriMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Ayako ItagakiMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Hiroko YamamotoMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Hiroshi SeshimaMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Naoki KurashimaMedical Engineering Center, Institute of Science Tokyo Hospital, Tokyo, Japan.
Soichiro IimoriDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.
Shotaro NaitoDepartment of Nephrology, Institute of Science Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionRheocarna has attracted attention as an alternative therapy for severe chronic limb-threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non-dialysis patients.

methodsFour non-dialysis patients who received Rheocarna were studied to determine the conditions under which it was administered and its effectiveness.

resultsThe ulcer healed completely, but two patients required skin grafting. The treatment time and blood flow rate were 90-120 min and 50-80 mL/min, respectively. The processed volume was about 1.0 times the circulating blood volume, and the removal rate of low-density lipoprotein and fibrinogen was about 10%-15%.

conclusionThe ulcers healed despite the removal rate of low-density lipoprotein and fibrinogen being small. To our knowledge, this is the first report on the treatment conditions and effectiveness of Rheocarna in non-dialysis patients.

Indexed as

IschemiaFibrinogenHumansLipoproteins, LDLSkin TransplantationTime FactorsTreatment OutcomeFibrinogenLipoproteins, LDLchronic lime‐threating ischemiafibrinogennon‐dialysis patientsRheocarnavascular access

Identifiers

PMID40229218
PMCPMC12213312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.